ATE478602T1 - Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen - Google Patents

Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen

Info

Publication number
ATE478602T1
ATE478602T1 AT05858653T AT05858653T ATE478602T1 AT E478602 T1 ATE478602 T1 AT E478602T1 AT 05858653 T AT05858653 T AT 05858653T AT 05858653 T AT05858653 T AT 05858653T AT E478602 T1 ATE478602 T1 AT E478602T1
Authority
AT
Austria
Prior art keywords
protein
receptor
precursor
polypeptide
alpha
Prior art date
Application number
AT05858653T
Other languages
English (en)
Inventor
S Karumanchi
Vikas Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE478602T1 publication Critical patent/ATE478602T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/321Arterial hypertension
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05858653T 2004-12-15 2005-12-15 Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen ATE478602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627504P 2004-12-15 2004-12-15
PCT/US2005/045805 WO2007053161A2 (en) 2004-12-15 2005-12-15 Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
ATE478602T1 true ATE478602T1 (de) 2010-09-15

Family

ID=38006337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05858653T ATE478602T1 (de) 2004-12-15 2005-12-15 Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen

Country Status (11)

Country Link
US (1) US7955805B2 (de)
EP (1) EP1839057B1 (de)
JP (1) JP2008523816A (de)
KR (1) KR20070092737A (de)
CN (1) CN101299962A (de)
AT (1) ATE478602T1 (de)
AU (1) AU2005337873A1 (de)
BR (1) BRPI0519096A2 (de)
CA (1) CA2591142A1 (de)
DE (1) DE602005023216D1 (de)
WO (1) WO2007053161A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
ATE519109T1 (de) 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US7230561B2 (en) * 2005-01-27 2007-06-12 Micron Technology, Inc. Programmable integrating ramp generator and method of operating the same
CA2602963A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
CN101616927A (zh) * 2005-09-15 2009-12-30 迪爱麦有限公司 诊断先兆子痫的方法
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2008089520A1 (en) * 2007-01-25 2008-07-31 Crc For Asthma And Airways Ltd Method of diagnosis
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
EP2037278A1 (de) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Gefäßmarker bei der Neumodellierung von Herzkrankheiten
US20110171650A1 (en) * 2008-09-16 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Gene expression related to preeclampsia
CN105021821B (zh) 2008-10-31 2018-05-11 耶鲁大学 先兆子痫检测和治疗的方法和组合物
CN102300875B (zh) * 2009-01-28 2014-07-16 财团法人工业技术研究院 肾病相关的生物标记
WO2012125641A1 (en) 2011-03-17 2012-09-20 Cedars-Sinai Medical Center Diagnostic biomarker to predict women at risk for preterm delivery
AU2011311997A1 (en) * 2010-02-26 2013-04-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3336552A3 (de) * 2010-11-29 2018-07-25 Mote Marine Laboratory, Inc. Bestimmung der geschlechtsmerkmale von fischen mittels peptidhormonen
KR101114446B1 (ko) * 2011-02-25 2012-02-24 건국대학교 산학협력단 프로테오믹스기법을 이용한 임신중독 특이 표지 단백질 및 진단방법
CN102192987B (zh) * 2011-02-25 2014-04-02 复旦大学附属上海市第五人民医院 一种用于妊娠高血压疾病诊断的试剂盒
AU2012346594B2 (en) * 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
JP2015505368A (ja) * 2012-01-06 2015-02-19 ビージー メディシン, インコーポレイテッド 妊娠高血圧腎症および関連状態のリスク評価および検出のためのガレクチン−3の使用
CN104634982B (zh) * 2013-11-06 2016-08-17 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN103760340B (zh) * 2014-01-28 2016-11-23 成都创宜生物科技有限公司 以flrg作为标志物制备检测工具的应用及检测工具
ES2817417T3 (es) 2014-04-10 2021-04-07 Univ Yale Métodos y composiciones para la detección de proteínas mal plegadas
US20160130553A1 (en) 2014-05-15 2016-05-12 Kellbenx Incorporated PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING
US12202890B1 (en) 2014-11-07 2025-01-21 Kellbenx Incorporated Antibodies for detection and enrichment of fetal cells and their use
ES2955883T3 (es) 2015-06-19 2023-12-07 Sera Prognostics Inc Pares de biomarcadores para la predicción del parto prematuro
CN106771266A (zh) * 2017-01-12 2017-05-31 广州市丰华生物工程有限公司 抑制素a定量检测试剂盒及其制备方法
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α1−アンチキモトリプシンを含むバイオマーカー
US12436155B2 (en) * 2020-04-16 2025-10-07 Kalia Health, Inc. Preeclampsia screening device and methods measuring activin and/or inhibin A
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN114075281B (zh) * 2021-11-16 2023-04-18 福州迈新生物技术开发有限公司 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) * 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
US6620590B2 (en) * 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
AU5331298A (en) 1996-12-23 1998-07-17 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US6376199B1 (en) * 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
EP1417971A3 (de) 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) * 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
WO2003057916A2 (en) * 2002-01-09 2003-07-17 Riken Cancer profiles
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
DE10333105B3 (de) * 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
WO2005017192A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
AU2004276791B2 (en) * 2003-09-23 2010-07-01 Beth Israel Deaconess Medical Center Screening for gestational disorders
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
ATE519109T1 (de) * 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
JP2009538915A (ja) 2006-05-31 2009-11-12 ベス イスラエル ディーコネス メディカル センター 妊娠の合併症を診断および治療する方法

Also Published As

Publication number Publication date
CA2591142A1 (en) 2007-05-10
WO2007053161A2 (en) 2007-05-10
WO2007053161A3 (en) 2007-11-29
EP1839057B1 (de) 2010-08-25
BRPI0519096A2 (pt) 2008-12-23
US20060166277A1 (en) 2006-07-27
AU2005337873A1 (en) 2007-05-10
HK1115286A1 (en) 2008-11-28
CN101299962A (zh) 2008-11-05
DE602005023216D1 (de) 2010-10-07
EP1839057A4 (de) 2008-12-31
KR20070092737A (ko) 2007-09-13
JP2008523816A (ja) 2008-07-10
US7955805B2 (en) 2011-06-07
EP1839057A2 (de) 2007-10-03

Similar Documents

Publication Publication Date Title
DE602005023216D1 (de) Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
Mooney et al. Suppressors of cytokine signaling-1 and-6 associate with and inhibit the insulin receptor: a potential mechanism for cytokine-mediated insulin resistance
Kennedy et al. CCN2 is necessary for the function of mouse embryonic fibroblasts
JP2008523816A5 (de)
Xu et al. Expression of TGF-β signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells
Vogt et al. ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth
Sisto et al. TGFβ1-Smad canonical and-Erk noncanonical pathways participate in interleukin-17-induced epithelial–mesenchymal transition in Sjögren's syndrome
Kobayashi et al. The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis
Bumke et al. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study
Mentlein et al. Functional significance of vascular endothelial growth factor receptor expression on human glioma cells
Houri et al. The Coxsackievirus and Adenovirus Receptor (CAR) undergoes ectodomain shedding and regulated intramembrane proteolysis (RIP)
Zhang et al. XCL 1‐XCR 1 pathway promotes trophoblast invasion at maternal‐fetal interface by inducing MMP‐2/MMP‐9 activity
JP2010512730A5 (de)
Bleuel et al. Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors
Nagashima et al. Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis.
KR20100044793A (ko) 신경퇴행성 질환에서 cd44 접목 변이체들
Kobayashi et al. The contribution of leukemia inhibitory factor (LIF) for embryo implantation differs among strains of mice
Xu et al. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells
AbdelHafez et al. Growth differentiation factor myostatin regulates epithelial‐mesenchymal transition genes and enhances invasion by increasing serine protease inhibitors E1 and E2 in human trophoblast cells
Luchetti et al. Scleroderma fibroblasts constitutively express the long pentraxin PTX3
US10415093B2 (en) Method for diagnosing and monitoring inflammatory disease progression
Kikuchi et al. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells
Li et al. Serum response factor, its cofactors, and epithelial–mesenchymal signaling in urinary bladder smooth muscle formation
Nayeem et al. Paracrine communication modulates production of Wnt antagonists and COX1-mediated prostaglandins in a decidual-trophoblast co-culture model
Lecca et al. Fibrotic response in fibroblasts from congenital disorders of glycosylation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties